Teva Reports Fourth Quarter and Full Year 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Teva Pharma (TEVA) Tops Q4 EPS by 4c
February 9, 2022 7:01 AM ESTTeva Pharma (NYSE: TEVA) reported Q4 EPS of $0.77, $0.04 better than the analyst estimate of $0.73. Revenue for the quarter came in at $4.1 billion versus the consensus estimate of $4.29 billion.
GUIDANCE:
Teva Pharma sees Q1 2022 EPS of $2.40-$2.60, versus the consensus of... More
